HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

23-valent pneumococcal capsular polysaccharide vaccine

for treatment of HIV-infected patients
Also Known As:
23-valent vaccine; PPSV23; Pneumo-23; Pneumovax 23
Networked: 190 relevant articles (16 outcomes, 42 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Buchwald, Ulrike K: 6 articles (03/2022 - 01/2021)
2. Musey, Luwy: 6 articles (03/2022 - 01/2016)
3. Kawakami, Kenji: 6 articles (01/2020 - 06/2015)
4. Song, Joon Young: 5 articles (01/2022 - 08/2015)
5. Kobayashi, Miwako: 5 articles (02/2021 - 09/2015)
6. Oishi, Kazunori: 5 articles (10/2020 - 06/2015)
7. Kim, Woo Joo: 4 articles (01/2022 - 08/2015)
8. Noh, Ji Yun: 4 articles (01/2022 - 08/2015)
9. Folaranmi, Temitope: 4 articles (01/2021 - 01/2021)
10. Iino, Tomoharu: 4 articles (01/2021 - 01/2018)

Related Diseases

1. Pneumococcal Infections
01/01/2021 - "Furthermore, administration of PPSV23 given either 8 weeks or 26 weeks after PCV13 elicited serotype-specific OPA GMTs to serotypes unique to PPSV23, which could provide earlier protection against pneumococcal disease caused by these serotypes in comparison with the current Advisory Committee on Immunization Practices recommended interval of at least 12 months."
12/31/2023 - "This subgroup analysis from a phase 3 study evaluated the safety, tolerability, and immunogenicity of sequential administration of either V114 (a 15-valent PCV containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) or PCV13, followed 6 months later by PPSV23, in immunocompetent adults 18-49 years of age with pre-defined risk factors for pneumococcal disease. "
10/01/2021 - "We found that the recent introduction of an age-based vaccination programme offering PPSV23 vaccination to the population of persons aged 65+ in Denmark will lead to a societal gain of EUR 72.0 million and prevent 19,707 cases of pneumococcal disease and 1,308 deaths per 1 million persons during the five-year study period.Similarly"
01/01/2000 - "The study results indicated that 96% of the serotypes involved in severe pneumococcal diseases were included in the 23-valent vaccine and that S. "
09/16/2022 - "Risk-based recommendations on use of PPSV23 for persons aged 2-18 years with certain underlying medical conditions§ that increase the risk for pneumococcal disease have not changed."
2. Pneumonia (Pneumonitis)
3. Pneumococcal Pneumonia
4. Chronic Obstructive Pulmonary Disease (COPD)
5. Streptococcal Infections (Streptococcal Infection)

Related Drugs and Biologics

1. Vaccines
2. Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)
3. Conjugate Vaccines
4. Polysaccharides (Glycans)
5. Influenza Vaccines (Influenza Vaccine)
6. Purinergic P1 Receptors (Adenosine Receptor)
7. Antibodies
8. Herpes Zoster Vaccine
9. Antigens
10. Hepatitis B Vaccines (Hepatitis B Vaccine)

Related Therapies and Procedures

1. Therapeutics
2. Cochlear Implants (Cochlear Implant)
3. Splenectomy
4. Cochlear Implantation
5. Antibiotic Prophylaxis